<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787072</url>
  </required_header>
  <id_info>
    <org_study_id>D3801C00001</org_study_id>
    <nct_id>NCT00787072</nct_id>
  </id_info>
  <brief_title>AZD8075 Single Ascending Dose Study</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD8075 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety, tolerability and pharmacokinetics of single
      ascending oral doses of AZD8075 in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After reports of turbidity in urine in 4 of 8 volunteers in the 4th cohort, the study was
    halted temporarily.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables (ECG, adverse events, blood pressure, pulse, body temp, safety lab)</measure>
    <time_frame>Frequent sampling occasions during study days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK variables</measure>
    <time_frame>Frequent sampling occasions during study days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8075</intervention_name>
    <description>Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral suspension</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed, written and dated informed consent prior to any study specific
             procedures.

          -  Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no
             more than 100 kg.

          -  Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products)
             for &gt;6 months prior to study start.

        Exclusion Criteria:

          -  Any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the result of the study, or the subject's ability to participate

          -  Any clinically relevant abnormal findings in physical examination, clinical chemistry,
             haematology, urinalysis, vital signs (vital signs (ie, supine BP and pulse) or ECG at
             baseline, which, in the opinion of the investigator, may put the subject at risk.

          -  Participation in another investigational drug study within 3 months before Visit 2 or
             participation in a method development study (no drug) 1 month prior to Visit 2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Pettersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang KÃ¼hn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <last_update_submitted>November 30, 2010</last_update_submitted>
  <last_update_submitted_qc>November 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christer Hultquist, Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Lund, Sweden</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

